Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 4, 2001, Pages 285-292

  Nishinaka, Yumiko ^a   Nakamura, Hajime ^a   Masutani, Hiroshi ^a   Yodoi, Junji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Reactive oxygen species; Redox regulation; Therapy; Thioredoxin

Indexed keywords

CARRIER PROTEIN; REACTIVE OXYGEN METABOLITE; THIOREDOXIN;

ANIMAL; APOPTOSIS; DRUG EFFECT; HUMAN; IMMUNOLOGY; IN VITRO STUDY; INTRACELLULAR FLUID; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; APOPTOSIS; CARRIER PROTEINS; HUMAN; IN VITRO; INTRACELLULAR FLUID; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; THIOREDOXIN;

EID: 0035237261     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. ADLER V., YIN Z., TEW K. D. and RONAI Z. (1999): Role of redox potential and reactive oxygen species in stress signaling. Oncogene, 18, 6104-6111.
2. ARRIGO A. P. (1999): Gene expression and the thiol redox state. Free Radic. Biol. Med., 27, 936-944.
3. ASLUND F. and BECKWITH J. (1999): The thioredoxin superfamily: redundancy, specificity, and gray-area genomics. J. Bacteriol., 181, 1375-1379.
4. BERTINI R., HOWARD O. M., DONG H. F., OPPENHEIM J. J., BIZZARRI C., SERGI R., CASELLI G., PAGLIEI S., ROMINES B., WILSHIRE J. A., MENGOZZI M., NAKAMURA H., YODOI J., PEKKARI K., GURUNATH R., HOLMGREN A., HERZENBERG L. A. and GHEZZI P. (1999): Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J. Exp. Med., 189, 1783-1789.
5. BUTTERFIELD L. H., MERINO A., GOLUB S. H. and SHAU H. (1999): From cytoprotection to tumor suppression: The multifunctorial role of peroxiredoxins. Antioxidants Redox Signaling, 1, 385-402.
6. BUTTKE T. M. and SANDSTROM P. A. (1994): Oxidative stress as a mediator of apoptosis. Immunol. Today, 15, 7-10.
7. EMA M., HIROTA K., MIMURA J., ABE H., YODOI J., SOGAWA K., POELLINGER L. and FUJII-KURIYAMA Y. (1999): Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J., 18, 1905-1914.
8. FLOHE L., BRIGELIUS-FLOHE R., SALIOU C., TRABER M. G. and PACKER L. (1997): Redox regulation of NF-κ B activation. Free Radic. Biol. Med., 22, 1115-1126.
9. HAYASHI S., HAJIRO-NAKANISHI K., MAKINO Y., EGUCHI H., YODOI J. and TANAKA H. (1997): Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res., 25, 4035-4040.
10. HAYES J. D. and MCLELLAN L. I. (1999): Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic. Res., 31, 273-300.
11. HIROTA K., MATSUI M., IWATA S., NISHIYAMA A., MOROI K. and YODOI J. (1997): AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA, 94, 3633-3638.
12. HIROTA K., MURATA M., SACHI Y., NAKAMURA H., TAKEUCHI J., MORI K. and YODOI J. (1999): Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κ B. J. Biol. Chem., 274, 27891-27897.
13. HOLMGREN A. (1985): Thioredoxin. Ann. Rev. Biochem., 54, 237-271.
14. HOLMGREN A. (1995): Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure, 3, 239-243.
15. HORI K., HIRASHIMA M., UENO M., MATSUDA M., WAGA S., TSURUFUJI S. and YODOI J. (1993): Regulation of eosinophil migration by adult T cell leukemia-derived factor. J. Immunol., 151, 5624-5630.
16. HOTTA M., TASHIRO F., IKEGAMI H., NIWA H., OGIHARA T., YODOI J. and MIYAZAKI J. (1998): Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J. Exp. Med., 188, 1445-1451.
17. ICHIJO, H. (1999): From receptors to stress-activated MAP kinases. Oncogene, 18, 6087-6093.
18. LAZO J. S., KUO S. M., WOO E. S. and PITT B. R. (1998): The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem. Biol. Interact., 111-112, 255-262.
19. LOETSCHER P., MOSER B. and BAGGIOLINI M. (2000): Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv. Immunol., 74, 127-180.
20. MAKINO Y., OKAMOTO K., YOSHIKAWA N., AOSHIMA M., HIROTA K., YODOI J., UMESONO K., MAKINO I. and TANAKA H. (1996): Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J. Clin. Invest., 98, 2469-2477.
21. MASUTANI H., HIROTA K., SASADA T., UEDA-TANIGUCHI Y., TANIGUCHI Y., SONO H. and YODOI J. (1996): Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I Tax. Immunol. Lett., 54, 67-71.
22. MATES J. M., PEREZ-GOMEZ C. and NUNEZ DE CASTRO I. (1999): Antioxidant enzymes and human diseases. Clin. Biochem., 32, 595-603.
23. MATSUDA M., MASUTANI H., NAKAMURA H., MIYAJIMA S., YAMAUCHI A., YONEHARA S., UCHIDA A., IRIMAJIRI K., HORIUCHI A. and YODOI J. (1991): Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J. Immunol., 147, 3837-3841.
24. MATSUI M., OSHIMA M., OSHIMA H., TAKAKU K., MARUYAMA T., YODOI J. and TAKETO M. M. (1996): Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev. Biol., 178, 179-185.
25. MATTHEWS J. R., WAKASUGI N., VIRELIZIER J. L., YODOI J. and HAY R. T. (1992): Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res., 20, 3821-3830.
26. NAKAMURA H., BAI J., NISHINAKA Y., UEDA S., SASADA T., OHSHIO G., IMAMURA M., TAKABAYASHI A., YAMAOKA Y. and YODOI J. (2000): Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect. Prev., 24, 53-60.
27. NAKAMURA H., DEROSA S., ROEDERER M., ANDERSON M. T., DUBS J. G., YODOI J., HOLMGREN A., HERZENBERG L. A. and HERZENBERG L. A. (1996): Elevation of plasma thioredoxin levels in HIV infected individuals. Int. Immunol., 8, 603-611.
28. NAKAMURA H., MASUTANI H., TAGAYA Y., YAMAUCHI A., INAMOTO T., NANBU Y., FUJII S., OZAWA K. and YODOI J. (1992): Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer, 69, 2091-2097.
29. NAKAMURA H., MATSUDA M., FURUKE K., KITAOKA Y., IWATA S., TODA K., INAMOTO T., YAMAOKA Y., OZAWA K. and YODOI J. (1994): Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide [published erratum appears in Immunol. Lett., 1994, 42, 213]. Immunol. Lett., 42, 75-80.
30. NAKAMURA H., NAKAMURA K. and YODOI J. (1997): Redox regulation of cellular activation. Annu. Rev. Immunol., 15, 351-369.
31. NILSSON J., SÖDERBERG O., NILSSON K. and ROSEN A. (2000): Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood, 95, 1420-1426.
32. NISHIYAMA A., MATSUI M., IWATA S., HIROTA K., MASUTANI H., NAKAMURA H., TAKAGI Y., SONO H., GON Y. and YODOI J. (1999): Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem., 274, 21645-21650.
33. NISHIYAMA A., OHNO T., IWATA S., MATSUI M., HIROTA K., MASUTANI H., NAKAMURA H. and YODOI J. (1999): Demonstration of the interaction of thioredoxin with p40phox, a phagocyte oxidase component, using a yeast two-hybrid system. Immunol. Lett., 68, 155-159.
34. NOIVA R. (1999): Protein disulfide isomerase: the multifunctional redox chaperone of the endoplasmic reticulum. Semin. Cell. Dev. Biol., 10, 481-493.
35. OKAMOTO T., SAKURADA S., YANG J. P. and MERIN J. P. (1997): Regulation of NF-κ B and disease control: identification of a novel serine kinase and thioredoxin as effectors for signal transduction pathway for NF-κB activation. Curr. Top Cell. Regul., 35, 149-161.
36. PACKER L. and YODOI J. (eds.) (1999): Redox regulation of cell signaling and its clinical application. Marcel Dekker Inc., New York.
37. QIN J., CLORE G. M., KENNEDY W. M., HUTH J. R. and GRONENBORN A. M. (1995): Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF-κB. Structure, 3, 289-297.
38. QIN J., CLORE G. M., KENNEDY W. P., KUSZEWSKI J. and GRONENBORN A. M. (1996): The solution structure of human thioredoxin complexed with its target from Ref-1 reveals peptide chain reversal. Structure, 4, 613-620.
39. ROTHWELL D. G., BARZILAY G., GORMAN M., MORERA S., FREEMONT P. and HICKSON I. D. (1997): The structure and functions of the HAP1/Ref-1 protein. Oncol. Res., 9, 275-280.
40. SAITOH M., NISHITOH H., FUJII M., TAKEDA K., TOBIUME K., SAWADA Y., KAWABATA M., MIYAZONO K. and ICHIJO H. (1998): Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J., 17, 2596-2606.
41. SASADA T., IWATA S., SATO N., KITAOKA Y., HIROTA K., NAKAMURA K., NISHIYAMA A., TANIGUCHI Y., TAKABAYASHI A. and YODOI J. (1996): Redox control of resistance to cis-diamminedichloroplatium (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest., 97, 2268-2276.
42. SCHENK H., VOGT M., DROGE W. and SCHULZE-OSTHOFF K. (1996): Thioredoxin as a potent costimulus of cytokine expression. J. Immunol., 156, 765-771.
43. SCHULZE-OSTHOFF K., SCHENK H. and DROGE W. (1995): Effects of thioredoxin on activation of transcription factor NF-κB. Methods Enzymol., 252, 253-264.
44. SEN C. K., SIES H. and BAEUERLE P. A. (eds.) (2000): Antioxidant and redox regulation of genes. Academic Press, San Diego.
45. SILBERSTEIN D. S., ALI M. H., BAKER S. L. and DAVID J. R. (1989): Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics, and partial amino acid sequence of an active polypeptide [published erratum appears in J. Immunol., 1991, 147, 4408]. J. Immunol., 143, 979-983.
46. SILBERSTEIN D. S., MCDONOUGH S., MINKOFF M. S. and BALCEWICZ-SABLINSKA M. K. (1993): Human eosinophil cytotoxicity-enhancing factor. Eosinophil-stimulating and dithiol reductase activities of biosynthetic (recombinant) species with COOH-terminal deletions. J. Biol. Chem., 268, 9138-9142.
47. SONO H., TESHIGAWARA K., SASADA T., TAKAGI Y., NISHIYAMA A., OHKUBO Y., MAEDA Y., TATSUMI E., KANAMARU A. and YODOI J. (1999): Redox control of Epstein-Barr virus replication by human thioredoxin/ATL-derived factor: Differential regulation of lytic and latent infection. Antioxid. Redox Signal., 1, 155-165.
48. SPYROU, G., ENMARK E., MIRANDA-VIZUETE A. and GUSTAFSSON J.-A. (1997): Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem., 272, 2936-2941.
49. TAGAYA Y., MAEDA Y., MITSUI A., KONDO N., MATSUI H., HAMURO J., BROWN N., ARAI K., YOKOTA T., WAKASUGI H. and YODOI J. (1989): ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J., 8, 757-764.
50. TAKAGI Y., MITSUI A., NISHIYAMA A., NOZAKI K., SONO H., GON Y., HASHIMOTO N. and YODOI J. (1999): Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. USA, 96, 4131-4136.
51. TESHIGAWARA K., MAEDA M., NISHINO K., NIKAIDO T., UCHIYAMA T., TSUDO M., WANO Y. and YODOI J. (1985): Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J. Mol. Cell Immunol., 2, 17-26.
52. UEDA S., NAKAMURA H., MASUTANI H., SASADA T., YONEHARA S., TAKABAYASHI A., YAMAOKA Y. and YODOI J. (1998): Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J. Immunol., 161, 6689-6695.
53. UENO M., MASUTANI H., ARAI R. J., YAMAUCHI A., HIROTA K., SAKAI T., INAMOTO T., YAMAOKA Y., YODOI J. and NIKAIDO T. (1999): Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J. Biol. Chem., 274, 35809-35815.
54. WADA H., MURO K., HIRATA T., YODOI J. and HITOMI S. (1995): Rejection and expression of thioredoxin in transplanted canine lung. Chest, 108, 810-814.
55. WAKASUGI H., WAKASUGI N., TURSZ T., TAGAYA Y. and YODOI J. (1989): Production of an IL-1-like factor by 3B6 EBV-infected B cells. J. Immunol., 142, 2569-2570.
56. WAKASUGI N., TAGAYA Y., WAKASUGI H., MITSUI A., MAEDA M., YODOI J. and TURSZ T. (1990): Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I-and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc. Natl. Acad. Sci. USA, 87, 8282-8286.
57. WATSON J. A., RUMSBY M. G. and WOLOWACZ R. G. (1999): Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone. Biochem. J., 343 Pt 2, 301-305.
58. WELLS W. W., YANG Y., DEITS T. L. and GAN Z. R. (1993): Thioltransferases. Adv. Enzymol. Relat. Areas Mol. Biol., 66, 149-201.
59. YODOI J. and TURSZ T. (1991): ADF, a growth-promoting factor derived from adult T cell leukemia and homologous to thioredoxin: involvement in lymphocyte immortalization by HTLV-I and EBV. Adv. Cancer Res., 57, 381-411.
60. YODOI J. and UCHIYAMA T. (1992): Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation. Immunol. Today, 13, 405-411.